Therapeutic resistance and optimal drug sequencing in HER2-positive metastatic breast cancer: unmet needs and future perspectives.

Heliyon · 2024 · PMC10757006 · PMID 38163142

Europe PMC DOI

hedged sentence

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

a strong trendp = 0.067so close (0.05 < p ≤ 0.1)

Nevertheless, median OS with T-DM1 was still not reached in the DESTINY-Breast03, with an OS curve pointing towards better long-term trend compared to the same T-DM1 curve in the EMILIA, but with a strong trend on IPD survival analysis (p = 0.067) ( Fig. 1 B).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.